Study of Some Liver Function Tests in Patients with Breast Carcinoma During Chemotherapy Treatment at Oncology Center in Sebha City
Article Sidebar
-
Breast Carcinoma, Liver, Chemotherapy, Enzyme, Serum
Abstract
Breast carcinoma is the most common invasive carcinoma in all women worldwide, and it is also the leading cause of women dying in developing countries. This study aims to evaluate the effect of chemotherapy treatment effect on liver function tests in Libyan breast carcinoma patients. In this study, 40 cases, of which 30 are in various stages of breast carcinoma (28 female and 2 male) and the rest without carcinoma (group control), were selected from the Oncology Centre in Sebha city. Liver function tests, including total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) activities, were performed using the spectrophotometric technique. The cases were grouped according to their age (30 to 70 years, with an average age of 50 to 40 years). The mean values of AST, ALT, alkaline phosphatase, and total bilirubin in breast carcinoma patients during chemotherapy treatment were 32.1 ± 13.6 U/L, 11.9 ± 7.21 U/L, 631 ± 54.3 U/L, and 2.34 ± 1.73 mg/dl, respectively. These values were compared with those for group control, and no significant statistical differences were observed. In conclusion, the present study suggested that liver function tests of breast carcinoma patients during their chemotherapy treatment might not be an acceptable biochemical parameter for diagnosis and monitoring breast carcinoma.
Full text article
References
[1]-Parkin, D.;Bray, F. and Devesa, S., (2001), Cancer Burdens in the Year 2000-The Global Picture. Eur. J. Cancer, 37(8), 54–66.
[2]-Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin.,( 2015), Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, International journal of cancer,136(5), E359–E386.
[3]-Er O, Frye DK, Kau SW.,( 2008), Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy, Cancer J, 14, 62-68.
[4]-Jardines L, Callans LS, Torosian MH, (1993), Recurrent breast cancer: presentation, diagnosis, and treatment, Semin Oncol, 20, 538-547.
[5]-Chabner, B.A. and Roberts Jr., T.G., (2005), Timeline: Chemotherapy and the War on Cancer. Nature Reviews Cancer, 5, 65-72.
[6]-Swapna V.S, Veera Sudhakar, Dinesh Javerappa.,(2018) Study of Liver Function Tests in Breast Carcinoma Patients before and After Chemotherapy, International Journal of Biotechnology and Biochemistry, 14, 3, 177-184
[7]-Atalay G, Biganzoli L, Renard F, ( 2003), Clinical outcome of breast cancer patients with liver metastases alone in the anthracyclinetaxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials, Eur J Cancer, 39, 2439-2449.
[8]-Navarro VJ, Senior JR.,( 2006) , Drug-related hepatotoxicity, N Engl J Med, 9, 354:731.
[9]-Ishak KG, Zimmerman HJ.,( 1995), Morphologic spectrum of drug-induced hepatic disease, Gastroenterol ClinNorth Am, 24,759-86.
[10]-Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL ., (2003) , Prognostic factors for patients with hepatic metastases from breast cancer, Br J Cancer, 89(2), 284–290.
[11]-Brown JE, Cook RJ, Lipton A, Coleman RE., (2012), Serumlactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients, Clin Cancer Res, 18, 6348-6355.
[12]-Kumar K, Plasma lipid alteration and related biochemical studies in mammary tumour, Doctoral Thesis, University of Madras, India. 1991
[13]-Thangaraju M, Rameshbabu J, Vasavi H, Ilanchezhian S, Vinitha S, Sachdanandam P., (1998), The salubrious effect of tamaxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer women, Molecular and Cellular Biochemistry,185,85–94.
[14]-Alessandro Inno, Michele Basso, Fabio M Vecchio, Valentina A Marsico, Eleonora Cerchiaro, Ettore D'Argento, Cinzia Bagalà and Carlo Barone.,( 2011), Anastrozole-related acute hepatitis with autoimmune features: a case report, BMC Gastroenterology, 11,32
[15]-Ali AB, Alsonossi SA and Abdrahim FA.,(2020),Prostate Specific Antigen Protein Level as Biomarker in Breast Carcinoma Patients at Oncology Centrein SebhaCity/ Libya, Iraqi journal of science and technology.
[16]-Hill, B. A., (1971), Principle of Medical Statistical 9thEd, London, Lancet Limited b., 147, 383.
[17]-Jemal A, Siegel R, Xu J, et al.,( 2010), Cancer statistics, 2010, CA Cancer J Clin 60, 277-300.
[18]-Chauhan P, Yadav R , Kaushal Vand Beniwal P.,( 2016), Evaluation of serum biochemical profile of breast cancer patients, Health Sciences, 5(7),1-7
[19]-Akinsegun A , Abiodun P , Adewumi A , Adedoyin D ,Olajumoke O , Philip A , Sarah A,( 2013),Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria, Caspian J Intern Med,4,1,574-579.
[20]-Gomez-Raposo C, Zambrana Tever F, Sereno Moyano M, Lopez Gomez M, Casado E., (2010), Male Breast cancer. Cancer Treat Rev, 36,451-7.
[21]-Oluwole SF, FadiranOA, Odesanmi WO., (1987), Disease of breast in Nigeria. Br J Surg, 74,582-5.
[22]-Korde LA, Zujewski JA, Kamin L,(2010), Multidisplinary meeting on breast cancer, J Clin Oncol, 28, 2114-22.
[23]-Ihekwaba F, (1992), Breast Cancer in Nigeria. Br J Surg, 79, 771-5.
[24]-Devi LI, Ralte L, Ali MA., (2015) Serum Biochemical Profile of Breast cancer patients, European Journal of Pharmaceutical and Medical Research, 2(6), 210-214.
[25]-Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao YA.,( 2014), An Evaluation of Hepatotoxicity in Breast Cancer Patients Receiving Injection Doxorubicin, Ann Med Health Sci Res, 4(1), 74-79.
[26]-Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, Renukadevi D., (2000) Serum levels of bone alkaline phosphatase in breast and prostate cancer with bone metastasis, Indian J Clin Biochem,15,2,110-113.
[27]-Mishra S, Sharma DC, Sharma P.,( 2004) , Studies of biochemical parameters in breast cancer with and without Metastasis,Indian J Clin Biochem,19(1),71–75.
[28]-Stieber P, Mangal D, Ritzke C, Rossler N, KirschCM, Eiermann W ., (1992), Significance of bone alkaline phosphatase, CA15-3 and CEA in detection of bone metastasis during follow up of patients suffering from breast carcinoma, Eur J Clin Chem Clin Biochem, 30(12),809-814.
[29]-Vanhol, of VO, Vanoostrom AT, Lepoutre LG, DeBroe ME., (1992), Alkaline phosphates isoenzyme patterns in malignancy disease, Clin Chem,38(12), 2546-2551.
[30]-Liu Z, Ning H, Que S, Wang L, Qin X, Peng T., (2014) , Complex association between alanine aminotransferase activity and mortalityin general population: a systematic review and meta-analysis of prospective studies, PLoS One, 9(3),1410.
[31]-Chhabra RJ, Mangukiya k, Sharma N, Sharma R.,( 2015), Estimation of Serum Uric Acid and Bilirubin in BreastCancer. Sch Acad J Pharm, 4(7), 337-339.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the University of Sebha where authors who have published their articles in the journal of the university of Sebha should how they can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
Privacy Statement The names and e-mail addresses entered on the Sabha University Journal site will be used for the aforementioned purposes only and for which they were used.